European Pharmaceutical Review

FEBRUARY 8, 2023

GlobalData predicts Bristol-Myers Squibb’s Breyanzi and Gilead’s Yescarta are set to have high annual sales in the forecast period. It is set to retain its market-leading position as the most lucrative CD19 CAR-T agent in NHL, with annual sales reaching $1.7 Peak sales are anticipated to reach $1.3 billion in 2031.

Marketing 98

Marketing Sales Physicians Patients 98

Pharmaceutical Technology

MAY 26, 2023

These figures are only expected to grow in the coming years, with sales forecasted to reach over $150 billion by 2028. According to the findings, 39% of surveyed high-prescribing physicians believe that the optimal place for immune-oncology agents is in a first-line setting. This high compound annual growth rate of 23.6%

Marketing 105

Marketing Physicians Insurance Pharmaceutical 105

PM360

SEPTEMBER 21, 2023

Over the next few weeks, manufacturers will submit a range of clinical, marketing, sales, pricing, and patient data, and then meet with CMS to discuss submissions later this fall. After this period, CMS will begin to include physician-administered drugs covered under Part B in the program.

Manufacturing 111

Manufacturing Marketing Competition Physicians 111

Pharmaceutical Technology

SEPTEMBER 2, 2022

However, the lack of mature overall survival data for either agent means physicians will have to select therapy based on attributes other than long-term efficacy. According to GlobalData’s consensus analyst sales and forecast database, Carvykti is forecast to achieve the highest sales of the anti-BCMA biologics class, with $2.9

Food and Drug Administration 59

Food and Drug Administration FDA Sales Marketing 59

Clarivate

OCTOBER 25, 2023

The dearth of cancer drugs (only blood cancer drug Imbruvica made this first list) stems from CMS only pursuing negotiations for Part D drugs in 2026 and 2027, then expanding to Part B drugs in 2028. Part D cannot cover drugs covered under Part A or Part B , forcing them to be addressed separately.

Prescription 52

Prescription Physicians Manufacturing Healthcare 52

Clarivate

AUGUST 27, 2024

and ramped up sales of PFA systems in Europe. In our September 2023 report on the electrophysiology market, Clarivate projected that by 2028, PFA would represent 50% of the U.S. Increased appeal for dual-energy systems: Sometimes a situation calls for RF, but physicians like the ease and efficiency of PFA. s Farapulse.

Marketing 52

Marketing Competition FDA Electronics 52

PM360

APRIL 7, 2023

Pharma, formulary decision-makers, and contracting specialists must now track exact dates when drugs became available, then track the difference between average sales price (ASP) and Maximum Fair Price (MFP) to ensure provider reimbursement is correct.”

Marketing 52

Marketing Pharma Manufacturing Healthcare 52